No Data
Express News | Roivant Sciences And Organon Announce Merger Agreement For Dermavant Sciences; Roivant Publishes Investor Presentation On Transaction
Express News | Organon & Co -on Sept 17, Co & Unit Entered Into Agreement and Plan of Merger by Dermavant Sciences & Roivant Sciences
Why Investors Shouldn't Be Surprised By Organon & Co.'s (NYSE:OGN) Low P/E
Sharp Sword! The FTC sues three major pharmaceutical 'middlemen', vowing to correct the distorted chain of interests.
①The USA FTC announced on its official website that it has filed a lawsuit against three major pharmaceutical benefit managers and their affiliated organizations, accusing them of engaging in anti-competitive and unfair rebate practices; ② The FTC also "explicitly stated" in the declaration that it is deeply concerned about the roles played by Eli Lilly, Novo-Nordisk, and Sanofi, insulin pharmaceutical companies, and may suggest in future enforcement actions to prosecute these pharmaceutical manufacturers.
Barclays Maintains Organon & Co(OGN.US) With Buy Rating, Maintains Target Price $26
Barclays Keeps Their Buy Rating on Organon (OGN)
Money Thrill : Not Only a solar player, "Our generation fleet of nuclear, hydro, wind, and solar generation facilities powers"